← Back to Patent Explorer
US4994367A Expired / Lapsed US ⏱️ 0.0 years remaining

Extended shelf life platelet preparations and process for preparing the same

Assignee: American Red Cross
•
Filing: 1988-10-07
•
Granted: 1991-02-19
•
Expires: 2008-10-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A first aspect of the present invention is a blood platelet preparation comprising blood platelets, an adenylate cyclase stimulator, a phosphodiesterase inhibitor, a thrombin inhibitor, and a plasmin inhibitor. A second aspect of the present invention is a plasma-free platelet storage medium containing dextrose, sodium citrate, sodium bicarbonate, and a platelet activation inhibitor, with a preferred platelet activation inhibitor comprising an adenylate cyclase stimulator in combination with a phosphodiesterase inhibitor. A third aspect of the present invention is a process for producing a plasma-free platelet preparation comprising producing platelet-rich plasma (PRP) from whole blood, adding a platelet activation inhibitor thereto, centrifuging the PRP to deposit the platelets on the bottom of the centrifuge container, removing the platelet-free plasma supernatant therefrom and adding a plasma-free liquid platelet storage medium thereto. A preferred platelet activation inhibitor for the process comprises an adenylate cyclase stimulator in combination with a phosphodiesterase inhibitor. A preferred adenylate cyclase stimulator is Prostaglandin El, a preferred phosphodiesterase inhibitor is Theophylline, a preferred plasmin inhibitor is Aprotinin, and a preferred thrombin inhibitor is N-(2-naphthylsulfonylglycyl)-D,L-amidinophenylalaninpiperidide.

Inventors

  • 👤 Arthur P. Bode
  • 👤 William A. L. Heaton
  • 👤 Stein Holme
  • 👤 David T. Miller

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 03:14
CPC Classifications
A; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/122; A01N1/126

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 83 words
A blood platelet preparation, comprising: blood platelets; an adenylate cyclase stimulator in an amount effective to increase the production of adenosine 3', 5'cyclic phosphate (cAMP) in said blood platelets; a phosphodiesterase inhibitor in an amount effective to reduce the degradation of cAMP in said blood platelets; a thrombin inhibitor in an amount effective to reduce the stimulation of said blood platelets by thrombin; and a plasmin inhibitor in an amount effective to reduce the degradation of cell surface proteins on said blood platelets.
Claim 2
Dependent Claim 83 words
A blood platelet preparation, comprising: blood platelets; an adenylate cyclase stimulator in an amount effective to increase the production of adenosine 3', 5'cyclic phosphate (cAMP) in said blood platelets; a phosphodiesterase inhibitor in an amount effective to reduce the degradation of cAMP in said blood platelets; a thrombin inhibitor in an amount effective to reduce the stimulation of said blood platelets by thrombin; and a plasmin inhibitor in an amount effective to reduce the degradation of cell surface proteins on said blood platelets.
Claim 3
Dependent Claim 16 words
A blood platelet preparation as claimed in claim 1, wherein said preparation further comprises blood plasma.
Claim 4
Dependent Claim 16 words
A blood platelet preparation as claimed in claim 1, wherein said preparation comprises a platelet concentrate.
Claim 5
Dependent Claim 16 words
A blood platelet preparation as claimed in claim 1, wherein said preparation is a plasma-free preparation.
Claim 6
Dependent Claim 16 words
A blood platelet preparation according to claim 1, wherein said adenylate cyclase stimulator is prostaglandin E1.
Claim 7
Dependent Claim 14 words
A blood platelet preparation according to claim 1, wherein said phosphodiesterase inhibitor is theophylline.
Claim 8
Dependent Claim 22 words
A blood platelet preparation according to claim 1, wherein said thrombin inhibitor is selected from the group consisting of hirudin and N-(2-naphthylsulfonylglycyl)-D,L-amidinophenylalaninpiperidine.
Claim 9
Dependent Claim 14 words
A blood platelet preparation according to claim 1, wherein said plasmin inhibitor is aprotinin.
Claim 10
Dependent Claim 43 words
A blood platelet preparation according to claim 1, wherein said adenylate cyclase stimulator is prostaglandin E1: wherein said phosphodiesterase inhibitor is theophylline; wherein said thrombin inhibitor is selected from the group consisting of hirudin and N-(2-naphthylsulfonylglycly)-D,L-amidinophenylalaninpiperidine; and wherein said plasmin inhibitor is aprotinin.
Claim 11
Dependent Claim 29 words
A blood platelet preparation according to claim 1 or 9 in a container having a surface to volume ration of between about 3 to 5 square centimeters per milliliter.
Claim 12
Dependent Claim 26 words
A blood platelet preparation according to claim 1 or 9 in a container having a surface to volume ration of about 4 square centimeters per milliliter.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-02-18 1994-08-20 1995-02-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-02-18 1998-08-20 1999-02-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-02-18 2002-08-20 2003-02-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag